Several anticancer therapies, particularly anthracyclines and targeted agents such as human epidermal growth factor receptor 2 (HER-2) inhibitors (e.g., trastuzumab), have significantly improved survival rates in patients with breast cancer and other malignancies [1]. This evidence concerns the gene ERBB2 and breast carcinoma.